Pediatrix Medical Group (NYSE:MD) Cut to Hold at StockNews.com

StockNews.com lowered shares of Pediatrix Medical Group (NYSE:MD) from a buy rating to a hold rating in a report released on Thursday.

Several other equities research analysts also recently commented on MD. Jefferies Financial Group increased their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Truist Financial increased their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho upped their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Finally, UBS Group upped their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Pediatrix Medical Group has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Stock Up 1.4 %

Shares of MD stock opened at $14.96 on Thursday. The firm’s fifty day moving average price is $12.93 and its two-hundred day moving average price is $10.04. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $16.41. The firm has a market capitalization of $1.28 billion, a P/E ratio of -4.89, a PEG ratio of 2.10 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same quarter in the previous year, the business earned $0.29 earnings per share. Pediatrix Medical Group’s quarterly revenue was up .9% on a year-over-year basis. On average, equities analysts predict that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares in the company, valued at $343,783.80. This trade represents a 18.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,808 shares of company stock worth $751,277 over the last quarter. Company insiders own 2.00% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors have recently bought and sold shares of MD. Barclays PLC lifted its position in shares of Pediatrix Medical Group by 302.9% during the 3rd quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after acquiring an additional 106,817 shares during the period. Geode Capital Management LLC raised its stake in Pediatrix Medical Group by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock valued at $22,452,000 after purchasing an additional 45,155 shares in the last quarter. M&T Bank Corp raised its stake in Pediatrix Medical Group by 20.1% in the third quarter. M&T Bank Corp now owns 85,264 shares of the company’s stock valued at $988,000 after purchasing an additional 14,247 shares in the last quarter. Jane Street Group LLC grew its stake in Pediatrix Medical Group by 54.0% during the third quarter. Jane Street Group LLC now owns 303,283 shares of the company’s stock worth $3,515,000 after buying an additional 106,332 shares in the last quarter. Finally, Weiss Asset Management LP increased its holdings in Pediatrix Medical Group by 50.5% in the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock valued at $10,580,000 after buying an additional 306,143 shares during the period. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.